Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts
from its research and development portfolio will be presented at
the upcoming 2017 American Association for Cancer Research (AACR)
annual meeting in Washington, D.C. from April 1-5, 2017. These
abstracts include a clinical data presentation from the
dose-escalation phase of the Company’s ongoing trial of its
selective FGFR 1/2/3 inhibitor (INCB54828), and well as preclinical
data from its small molecule inhibitor programs targeting PI3Kδ
(INCB50465), LSD1 (INCB59872), JAK1 (INCB52793), BRD/BET (INCB54329
and INCB57643) and FGFR4 (INCB62079) and from its epacadostat, OX40
(INCAGN1949) and GITR (INCAGN1876) immuno-oncology programs.
“The 20 abstracts to be presented at the upcoming AACR annual
meeting underscore the breadth and potential of our innovative
pipeline of oncology product candidates,” stated Reid Huber, Ph.D.,
Chief Scientific Officer, Incyte. “We are pleased to share these
new data with the scientific community, and look forward to
progressing these and the other clinical programs in our growing
portfolio.”
Key abstracts, including Incyte-sponsored and independent
investigator-sponsored studies, include:
Targeted therapies abstracts
Activity of the Selective FGFR 1, 2 and 3 Inhibitor INCB54828 in
Genetically-Defined Models of Triple-Negative Breast Cancer
(Abstract #531)
- Sunday, April 2, 2017, 1:00-5:00 p.m.
EDT, Poster Section 22
Preclinical Studies on Potential Therapeutic Combination
Partners for the Potent and Selective PI3K Inhibitor INCB50465 in
DLBCL (Abstract #143)
- Sunday, April 2, 2017, 1:00-5:00 p.m.
EDT, Poster Section 6
The Evaluation of INCB59872, an FAD-Directed Covalent Inhibitor
of LSD1, in Preclinical Models of Ewing Sarcoma (Abstract
#1162)
- Monday, April 3, 2017, 8:00-12:00 p.m.
EDT, Poster Section 5
The Novel FGFR4-selective Inhibitor INCB62079 is Efficacious in
Models of Hepatocellular Carcinoma Harboring FGF19 Amplification
(Abstract #1234)
- Monday, April 3, 2017, 8:00-12:00 p.m.
EDT, Poster Section 7
Mechanisms of Bromodomain and Extra-Terminal Motif Inhibitor
(BETi) Sensitivity in Triple-Negative Breast Cancer (TNBC)
(Abstract #1518)
- Monday, April 3, 2017, 8:00-12:00 p.m.
EDT, Poster Section 20
Selective Inhibition of FGFR4 by INCB62079 is Efficacious in
Models of FGF19- and FGFR4-Dependent Cancers (Abstract #2100)
- Monday, April 3, 2017, 1:00-5:00 p.m.
EDT, Poster Section 33
Combination of Epigenetic Regulation with Targeted Therapies
Significantly Enhances Anti-Tumor Effects in Hematologic Malignancy
Models (Abstract #2032)
- Monday, April 3, 2017, 1:00-5:00 p.m.
EDT, Poster Section 4
Preliminary Results from a Phase 1/2 Study of INCB54828, a
Highly Selective Fibroblast Growth Factor Receptor (FGFR)
Inhibitor, in Patients (pts) with Advanced Malignancies (Abstract
#CT111)
- Tuesday, April 4, 2017, 8:00-12:00 p.m.
EDT, Poster Section 33
INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit
expansion of AML (Abstract #3726)
- Tuesday, April 4, 2017, 8:00-12:00 p.m.
EDT, Poster Section 29
The LSD1 Specific Inhibitor INCB59872 Enhances the Activity of
Immune Checkpoint Blockade by Reshaping the Myeloid Compartment in
the Syngeneic 4T1 Mouse Mammary Tumor Model (Abstract #4635)
- Tuesday, April 4, 2017, 1:00-5:00 p.m.
EDT, Poster Section 27
The Selective Bromodomain Inhibitor, INCB54329 Targets both
Cancer Cells and the Tumor Microenvironment in the KC Inflammatory
Preclinical Model of Ductal Pancreatic Cancer (Abstract #5082)
- Wednesday, April 5, 2017, 8:00-12:00
p.m. EDT, Poster Section 2
BET Inhibitors INCB54329 and INCB57643 Display Significant
Activity in Androgen-Independent Prostate Cancer Models (Abstract
#5080)
- Wednesday, April 5, 2017, 8:00-12:00
p.m. EDT, Poster Section 2
Preclinical Characterization of the Potent and Selective BET
Inhibitor INCB57643 in Models of Hematologic Malignancies (Abstract
#5071)
- Wednesday, April 5, 2017, 8:00-12:00
p.m. EDT, Poster Section 2
Immuno-oncology abstracts
Inhibition of IDO1 with Epacadostat Enhances Anti-Tumor Efficacy
of PD-1 Blockade in a Syngeneic Glioblastoma (GBM) Model (Abstract
#572)
• Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section
25
Agonist Antibodies Targeting OX40 and GITR Enhance the Activity
of the IDO1-Selective Inhibitor Epacadostat in Preclinical Models
(Abstract #2618)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section
25
INCAGN1876, a Unique GITR Agonist Antibody that Facilitates GITR
Oligomerization (Abstract #3643)
• Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section
26
INCAGN1949, an Anti-OX40 Antibody with an Optimal Agonistic
Profile, with the Ability to Selectively Deplete Intratumoral
Regulatory T Cells in a Range of Tumor Indications (Abstract
#4703)
• Tuesday, April 4, 2017, 1:00-5:00 p.m. EDT, Poster Section
30
Trials-in-progress abstracts
Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate
the Efficacy and Safety of INCB54828 in Subjects with
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement (Abstract
#CT057)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section
33
Phase 2, Open-label, Multicenter Study of the Efficacy and
Safety of INCB54828 for Metastatic or Surgically Unresectable
Urothelial Carcinoma Harboring Fibroblast Growth Factor (FGF)/FGF
Receptor (FGFR) Alterations (Abstract #CT059)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section
33
Phase 2, Open-label, Multicenter Study of the Efficacy and
Safety of INCB54828 in Patients with Advanced, Metastatic, or
Surgically Unresectable Cholangiocarcinoma (CCA) With Inadequate
Response to Prior Therapy (Abstract #CT063)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section
33
Full session details and data presentations at the AACR 2017 can
be found here.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company’s website at
www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the presentation of data regarding the Company’s
development portfolio and the potential effectiveness of such
portfolio, contain predictions, estimates and other forward-looking
statements. These forward-looking statements are based on the
Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments and the risks related to the
efficacy or safety of the Company’s development pipeline, the
results of further research and development, the high degree of
risk and uncertainty associated with drug development, clinical
trials and regulatory approval processes, other market or economic
factors and competitive and technological advances; and other risks
detailed from time to time in the Company’s reports filed with the
Securities and Exchange Commission, including the Form 10-K for the
year ending December 31, 2016. Incyte disclaims any intent or
obligation to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170302005612/en/
Incyte CorporationMediaCatalina Loveman, +1
302-498-6171cloveman@incyte.comorInvestorsMichael Booth,
DPhil, +1 302-498-5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Sep 2023 to Sep 2024